Synaptogenix (NASDAQ:TAOX) Posts Earnings Results

Synaptogenix (NASDAQ:TAOX) posted its earnings results on Wednesday. The company reported $0.43 earnings per share for the quarter, FiscalAI reports. The business had revenue of $5.96 million during the quarter.

Synaptogenix Trading Down 5.5%

Shares of NASDAQ TAOX traded down $0.33 during midday trading on Wednesday, hitting $5.70. The company’s stock had a trading volume of 119,639 shares, compared to its average volume of 172,058. Synaptogenix has a 12-month low of $2.12 and a 12-month high of $11.98. The firm has a market cap of $42.59 million, a P/E ratio of -0.33 and a beta of 1.49. The business’s 50 day moving average is $5.32 and its two-hundred day moving average is $5.49.

Analyst Ratings Changes

Several research analysts recently commented on TAOX shares. Wall Street Zen lowered Synaptogenix from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.